GR-MD-02 regulatory update

FDA granted Fast Track designation for Galectin's GR-MD-02 to treat non-alcoholic steatohepatitis (NASH) with advanced hepatic fibrosis. The galectin-3 (LGALS3) and LGALS1 inhibitor is in Phase I te...